Medical Treatment of Breast Cancer Bone Metastasis: From Bisphosphonates to Targeted Drugs

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorErdogan, Bulent
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T10:55:10Z
dc.date.available2024-06-12T10:55:10Z
dc.date.issued2014
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBreast cancer bone metastasis causing severe morbidity is commonly encountered in daily clinical practice. It causes pain, pathologic fractures, spinal cord and other nerve compression syndromes and life threatening hypercalcemia. Breast cancer metastasizes to bone through complicated steps in which numerous molecules play roles. Metastatic cells disrupt normal bone turnover and create a vicious cycle to which treatment efforts should be directed. Bisphosphonates have been used safely for more than two decades. As a group they delay time to first skeletal related event and reduce pain, but do not prevent development of bone metastasis in patients with no bone metastasis, and also do not prolong survival. The receptor activator for nuclear factor kappa B ligand inhibitor denosumab delays time to first skeletal related event and reduces the skeletal morbidity rate. Radionuclides are another treatment option for bone pain. New targeted therapies and radionuclides are still under investigation. In this review we will focus on mechanisms of bone metastasis and its medical treatment in breast cancer patients.en_US
dc.identifier.doi10.7314/APJCP.2014.15.4.1503
dc.identifier.endpage1510en_US
dc.identifier.issn1513-7368
dc.identifier.issue4en_US
dc.identifier.pmid24641358en_US
dc.identifier.scopus2-s2.0-84896920836en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1503en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2014.15.4.1503
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19320
dc.identifier.volume15en_US
dc.identifier.wosWOS:000333670100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal Of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectBone Metastasisen_US
dc.subjectBisphosphonatesen_US
dc.subjectDenosumaben_US
dc.subjectTargeted Therapyen_US
dc.subjectPhase-Ii Trialen_US
dc.subjectSkeletal-Related Eventen_US
dc.subjectZoledronic Aciden_US
dc.subjectDouble-Blinden_US
dc.subjectRisk-Factorsen_US
dc.subjectMultiple-Myelomaen_US
dc.subjectProstate-Canceren_US
dc.subjectPain Palliationen_US
dc.subjectOsteoclast Formationen_US
dc.subjectOral Ibandronateen_US
dc.titleMedical Treatment of Breast Cancer Bone Metastasis: From Bisphosphonates to Targeted Drugsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu